Scynexis Inc.
- Address
- 1 Evertrust Plaza Floor 13th
Sponsor Overview
Specializations
Invasive candidiasis and candidemia
Scynexis Inc. focuses its clinical research on serious fungal infections, with particular attention to invasive candidiasis and candidemia. The company’s trial activity centers on treatment strategies for bloodstream and deep-seated Candida infections in adult patients.
- Systemic antifungal therapy
- Candida bloodstream infection
- Invasive fungal disease
Research in this area reflects interest in managing complex infections that require sequential intravenous and oral antifungal treatment approaches.
Echinocandin-based treatment pathways
The sponsor’s research includes echinocandin-based regimens as a core element of therapy for candidemia and invasive candidiasis. This area highlights the role of initial IV antifungal treatment in serious yeast infections.
- Intravenous antifungal therapy
- Step-down treatment
- Severe Candida infection management
Clinical interest extends to treatment sequences that transition from parenteral to oral antifungal therapy in patients with systemic infection.
Ibrexafungerp and oral antifungal therapy
Scynexis Inc. also investigates ibrexafungerp as an oral antifungal option within treatment regimens for invasive candidiasis and candidemia. This therapeutic area is linked to maintaining antifungal coverage after initial IV treatment.
- Oral step-down therapy
- Antifungal sequencing
- Systemic Candida treatment
The research landscape includes comparison with established oral antifungal options used after echinocandin therapy.
Comparative antifungal treatment
The company’s clinical interest includes comparative evaluation of antifungal regimens for bloodstream Candida infections. Its research activity is directed toward treatment options used after initial control of infection with intravenous echinocandin therapy.
- Therapeutic comparison
- Antifungal regimen selection
- Management of invasive yeast disease
This area is relevant to patients requiring continued antifungal treatment for serious Candida-related illness.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 3 Randomized Study of Echinocandin Followed by Ibrexafungerp vs. Echinocandin Followed by Fluconazole in Invasive Candidiasis/Candidemia |  Belgium Bulgaria France Germany Greece Italy Spain | Not Recruiting |
Data & Insights
This sponsor works with 7 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 31 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses1 trial180 other sponsors
Partnered Research Centres
31 centres- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Largo Del Pozzo 71, 41124 Modena
- Address
- Via Pozzuolo 330, 33100 Udine
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- 69 Rue Du Lieutenant Colonel Prudhon, 95107 Argenteuil
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Scynexis Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.